rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Chitosan Brushes vs Air-Abrasive Devices on Peri-implant Mucositis Treatment: A Randomized Clinical
Status: Recruiting

Bleeding on probing (0,1,2,3), plaque index (+,-) and pocket probing depth will be recorded for each visit. Before the procedure, the patient will be randomly assigned to one of four groups and records will be kept. In the frst visit of the patient, necessary actions will be taken according to the group to which the patient is assigned. The implant periphery of the patients assigned to the chitosan brush group will be debrided with a chitosan brush with circular movements. The implants of the patients assigned to the air abrasive device group will be cleaned in the same way with circular movements. The debrided area of both groups will be washed with sterile serum after the treatment. Patients will be called at the 2nd, 4th and 12th weeks and compared with the records kept.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Presence of peri-implant mucositis around at least one implant, Being over 18 years old, Being psychologically suitable, The teeth adjacent to the relevant implant are natural teeth, Having at least 1 implant in the maxillary or mandibular posterior region (teeth 4, 5, 6 and 7) and a cemented prosthesis that is not connected to other implants or teeth as its superstructure, Probing depth longer than 3 mm and shorter than 5 mm, Evidence of bleeding is required on probing.  Exclusion Criteria:  Pregnancy History of chemotherapy and/or radiotherapy received in the past or currently being received, Bone loss around the implant, Presence of an implant in the area adjacent to the relevant implant, Dentures combined with other implants or teeth, Screw-retained prostheses Uncontrolled diabetes - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - StdAgeList: Child, Adult, Older Adult
Probiotics for Gallstones in Post-bariatric Surgery Patients
Status: Recruiting

Obesity is an increasing epidemic worldwide and has a significant impact on human health and socioeconomics. Multiple studies have shown that bariatric surgery increases the risk of postoperative gallbladder stones. Contributing factors to gallstone formation include gallbladder motility and bile supersaturation due to rapid weight loss and cholesterol mobilization. At present, the prevention and treatment of gallbladder stones in obese patients after bariatric surgery are still controversial. In recent years, the study of ursodeoxycholic acid in preventing gallbladder stone formation after bariatric surgery has become a research hotspot. At the same time, other studies have shown that taking probiotics or digestive enzymes may improve gastrointestinal symptoms and improve quality of life after bariatric surgery. Therefore, the purpose of this study was to determine the ability of probiotics to prevent gallstone formation after bariatric surgery and to evaluate the impact of oral probiotics on quality of life in patients after bariatric surgery.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients receiving bariatric surgery for morbid obesity Patiets at ages between 20 to 60 y/o Patients willing to follow up regulary after bariatric surgery  Exclusion Criteria:  Patients having gallstones before bariatric surgery Patients refusing taking probiotics or refusing regular follow up after bariatric surgery - HealthyVolunteers: No - Gender: All - MinimumAge: 20 Years - MaximumAge: 60 Years - StdAgeList: Adult
A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumours With FGFR2 Alterations
Status: Not yet recruiting

The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations. Patients will be enrolled in two stages: dose escalation stage (Stage I) and expansion stage (Stage II).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The patient is willing and able to provide written informed consent and has the ability to comply with the study protocol Men or women, age ≥ 18 years at the time of signing informed consent. Histologically or cytologically confirmed surgically unresectable, locally advanced, metastatic solid tumor. ECOG score is 0 or 1. An expected survival of ≥ 12 weeks. Evaluable or measurable disease per RECIST v1.1. Adequate organ function, as measured by laboratory values.  Exclusion Criteria:  Active brain metastases. Have other malignancies within the past 3 years. The toxicity from previous anti-tumor treatment has not recovered to ≤ grade 1. Clinically significant corneal or retinal disease/keratopathy. Clinically significant cardiovascular disorders. Failure to swallow, chronic diarrhea, or presence of other factors affecting drug absorption. Known to be allergic to any study drug or any of its excipients. Any other diseases or clinical laboratory, etc that may affect the interpretation of the results, or renders the patients at high risk from treatment complications. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
A Comparative Study of Using Scorpion Antivenom Versus Scorpion Antivenom and Prazosin
Status: Recruiting

Interventional study designed for the evaluation of characters and the outcome of scorpion sting patients will admit to Sohag University Hospitals in 2 randomized groups. The first group will receive scorpion antivenom only whether by the intravenous or the intramuscular route of administration. The second group will receive a combination of prazosin plus scorpion antivenom whether by the intravenous or the intramuscular route of administration. Both groups will receive proper first aid and supportive treatment

Eligibility:
- EligibilityCriteria: Inclusion criteria:  History and clinical diagnosis of scorpion sting Admit in Sohag University hospitals During the period from February 2023 to July 2024. Accepting informed written consent from the case itself or the first degree relative if the case will underage or in a coma.  Exclusion Criteria:  .All other envenomation cases or poisoning will be excluded. - HealthyVolunteers: No - Gender: All - MinimumAge: 1 Year - MaximumAge: 70 Years - StdAgeList: Child, Adult, Older Adult
Diagnosis of HCM With AI-ECG
Status: Recruiting

The study aims to establish a diagnostic model of hypertrophic cardiomyopathy with artificial intelligence-enhanced electrocardiogram.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Diagnosed with HCM  Exclusion Criteria:  Patients with ventricular pacing - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study includes patients with HCM, and subjects without HCM as control. - SamplingMethod: Non-Probability Sample
Function and Morphological Characteristics of Meibomian Gland in Patients With Renal Anemia
Status: Recruiting

Renal anemia refers to anemia in which the absolute or relative production of erythropoietin (EPO) is insufficient due to various kidney diseases, and uremic toxins affect erythropoietin production and its lifespan. Common treatment drugs for renal anemia include erythropoietin EPO and Roxadustat (FG-4592).

Medical history information was collected from patients with renal anemia who visited the ophthalmology department with dry eye symptoms.

This study will help to determine the function and morphological characteristics of meibomian gland in patients with renal anemia

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  long-term use of Roxadustat or erythropoietin for renal anemia  Exclusion Criteria:  contact lens wearer, history of eye surgeries, systemic health conditions affecting ocular health and those who were unable to cooperate with examinations - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
Pinch Grafting Versus Second Intention Wound Healing for Mohs Micrographic Surgery Defects on the Scalp
Status: Recruiting

Oftentimes, following surgery on the scalp, wounds are left to heal by themselves. This is called "second intention." Open wounds left to heal on the scalp often take 8 weeks or more to completely heal. We are investigating how second intention closure compares to another established reconstruction technique, called "pinch graft." In the pinch graft technique, we numb and then shave off a thin piece of skin (usually from the groin area) and place it in the wound bed it (also known as "grafting"), to encourage growth of new healthy skin. This study will compare time-to-healing in the second intention method versus the pinch graft method.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18 years of age or older Able to give informed consent themselves Patient scheduled for cutaneous surgical procedure on the scalp with predicted second intention closure Willing to return for follow up visit Active user of MyChart Willing to send weekly messages until wound is healed  Exclusion Criteria:  Incarceration Under 18 years of age Pregnant women Unable to understand written and oral English Scalp wounds with planned primary repair reconstruction Surgical defects with bone exposure No MyChart access or use - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Tapestry Rotator Cuff Repair PMCF
Status: Not yet recruiting

The study design is a prospective, multi-center, single-arm, non-randomized, and noncontrolled post market clinical follow-up study involving orthopedic surgeons skilled in arthroscopic rotator cuff repair as determined by the Sponsor.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult, 21 years and older;  Patient with a diagnosis of a symptomatic primary partial-thickness or full-thickness tear of the supraspinatus and/or infraspinatus tendons amenable to repair that meets one of the following criteria:  Partial-thickness tear planned for standalone treatment (no surgical repair with sutures/suture anchors) with the Tapestry Biointegrative Implant, or Full-thickness tear planned for treatment with the Tapestry Biointegrative Implant as an adjunct to surgical repair (single or double row repair with sutures/suture anchors); Patient is able and willing to complete the protocol required follow-up; Patient is able and willing to sign the IRB approved informed consent; Independent of study participation, patient qualifies for arthroscopic rotator cuff repair and meets the approved indications for use of the commercially available Tapestry RC Biointegrative Implant System  Exclusion Criteria:  Hypersensitivity to bovine-derived materials or poly(D,L-lactide) materials; Patient with an irreparable or partially reparable rotator cuff tear; Revision rotator cuff repair; Off-label use of the study device; Patient is known to be pregnant or nursing; Patient is a prisoner; Patient is a known alcohol or drug abuser; Patient has a psychiatric illness, neurologic disorder, or cognitive deficit that will not allow for proper informed consent or compliance with study requirements; Patient is unable to tolerate magnetic resonance imaging (MRI), due to psychiatric or medical contraindications; Patient is unwilling or unable to give consent or to comply with the follow-up program; Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 21 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study population will include both males and females undergoing arthroscopic rotator cuff repair due to partial or full-thickness tears of the supraspinatus and/or infraspinatus tendon. - SamplingMethod: Non-Probability Sample
Canadian Bone Strength Development Study
Status: Recruiting

The goal of this project is to learn about differences in bone development between children with and without type-1 diabetes (T1D). The main questions this study aims to answer are:

Assess how and when sex-specific bone developmental trajectories in the leg and arm will differ between children with T1D and control cohorts relative to the critical period of rapid skeletal growth in puberty. It is hypothesized that children with T1D will have inferior bone development, particularly lower gains in bone strength.
Assess why bone trajectories differ between T1D and control cohorts by identifying the role of body composition, site-specific muscle force and physical activity on differences in bone properties in female and male children with and without T1D. It is hypothesized that children with T1D will have lower gains in lean mass, muscle force, number of daily bone impacts and minutes of moderate-vigorous physical activity and will be associated with inferior gains in bone development.
Assess why T1D may impair sex-specific bone development by exploring the role of disease-related factors (e.g., duration, glucose control, hormones and markers of bone turnover) and fracture history on bone trajectories of children with T1D. It is hypothesized that longer exposure to T1D, poorer glucose control, alterations in hormones, lower bone formation markers and higher history of fracture will be negatively associated with bone trajectories of children with T1D.

Participant's physical growth, bone growth, muscle strength, physical activity and nutrition habits will be assessed and followed up annually for up to 4 years.

Eligibility:
- EligibilityCriteria: Children with Type-I Diabetes:  Inclusion Criteria  Females: 10-11 years old. Males: 11 - 12 years old. Diagnosed with type-1 diabetes for at least 6 months. Capacity to give informed consent (patient and parent/guardian). Children with the capacity to give assent will do so in addition to parental consent.  Exclusion Criteria  Consuming any medications or have additional illnesses associated with bone health, osteoporosis (including renal disease, celiac disease, hypogonadism, hyperthyroidism) or altered physical growth (precocious puberty). Have gone through adolescent growth spurt at study entry.  Control Group (Typically Developing Children):  Inclusion Criteria  Females: 10-11 years old. Males: 11 - 12 years old. Capacity to give informed consent (patient and parent/guardian). Children with the capacity to give assent will do so in addition to parental consent.  Exclusion Criteria  Have an illness or are taking medications influencing bone health or physical growth. Evidence of pathologic low trauma or vertebral fracture(s). Have gone through adolescent growth spurt at study entry. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 10 Years - MaximumAge: 12 Years - StdAgeList: Child - StudyPopulation: primary care clinic, community sample - SamplingMethod: Probability Sample
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 1
Status: Not yet recruiting

This study consists of three aims focused on examining the feasibility of adding the Geriatric Resources and Assessment for the Care of Elders (GRACE) model to structured Annual Wellness Visits (AWVs) to improve patient and caregiver outcomes and reduce hospitalizations in older adults with complex health needs. The objectives are to:

Co-design a community-centric implementation strategy for the AWVs vs AWVs + GRACE -augmented care (AWV GRACE) study arms
Develop a referral pathway and algorithm to optimize enrollment of eligible participants
Conduct a pilot clinical trial to assess the feasibility of the AWV GRACE intervention.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  be 65 years of age or older be eligible for an AWV during the study period have a residential mailing address within a 45-mile radius of the Vanderbilt clinics have a working home/mobile telephone number where they can be reached be English or Spanish speaking be able to provide consent and /or have a proxy able to consent to study participation  Exclusion Criteria:  are receiving hospice care are currently housed at Long Term Care Facilities are incarcerated - HealthyVolunteers: No - Gender: All - MinimumAge: 65 Years - StdAgeList: Older Adult
A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
Status: Recruiting

The performance of the predictive models for severe oropharyngeal mucositis established using current oral mucosal contouring method was unsatisfactory in nasopharyngeal carcinoma (NPC). Whereas the predictive model of a mucosal contouring method based on swallowing-induced breakthrough pain exhibited better overall performance. The aim of this prospective, multicenter, observational study was to further explore the predictive efficacy of this mucosal delineation method for radiation-induced oropharyngeal mucositis in NPC.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Provide informed written consent. Age ≥ 18 years. Histologically confirmed as nasopharyngeal carcinoma, and currently undergoing radical radiotherapy or chemoradiotherapy. Complete and continuous records of oral / oropharyngeal mucositis grading, and self-reported swallowing-induced breakthrough pain.  Exclusion Criteria:  Existence of poor oral hygiene, untreated dental or periodontal diseases, and metal dental restorations. Current untreated or unresolved conditions like unstable heart diseases requiring treatment, and poorly controlled diabetes mellitus. Body mass index (BMI) <18.5. Unsuitable to participate in current study, according to researchers' assessment. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with nasopharyngeal carcinoma after receiving radical radiotherapy or chemoradiotherapy - SamplingMethod: Probability Sample
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Status: Not yet recruiting

The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.

Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.

Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after

curative-intended surgery and
adjuvant chemotherapy.

FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Pancreatic ductal adenocarcinoma, according to the assessment of the MDT. Age 18 years or older. Scheduled for curative intent surgical resection.  Exclusion Criteria:  Hereditary pancreatic cancer. Verified distant metastases. Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study. Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening. Pregnant or nursing woman, or in childbearing age and not willing to use contraception Adult subject to a legal protection Not covered by Health insurance Patient unable to understand and sign written informed consent. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with resected PDAC - SamplingMethod: Non-Probability Sample
Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy
Status: Not yet recruiting

This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Over 18 years old Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic Diagnosis of medically refractory pain secondary to diabetic neuropathy Presence of pain for 12 months Lower limb pain intensity score ≥4 on a visual analog scale DN4 ≥4 Pass pre-operative neuropsychological assessment (surgical group only) Capable of providing informed consent  Exclusion Criteria:  Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement Coagulopathy that cannot be corrected Unable to discontinue blood thinning medications Hemoglobin A1c level greater than 10 Presence of systemic infection Pregnancy - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Status: Not yet recruiting

Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.

There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.

The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.

FRENCH.MRD.CRLM is the French study and part of the european GUIDE.MRD project.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patient 18 years or older. Colorectal cancer liver metastasis or metastases, according to the assessment of the MDT. Metachronous and synchronous metastases will be included, as long as treatment intention of metastases resection is curative. In case of rare instances, where the liver metastases is removed before surgery of the primary tumor, postOP ctDNA is collected when the patient is considered completely tumor-free, i.e. after complete surgery of both the liver metastases and the primary tumor. Treatment is planned with curative intent (patients treated with RFA can be included, BUT in these cases a tissue sample from the primary CRC tumor is a requisite)  Exclusion Criteria:  Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome. Extrahepatic metastases Malignant colorectal polyps diagnosed after polypectomy. Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma) Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study. Liver cirrhosis CRLM intervention/surgery cannot be/was not performed with curative intent No tumor tissue available (preferably CRLM lesion, or alternatively primary tumor) Pregnant or nursing woman, or in childbearing age and not willing to use contraception Protected and vulnerable adult Not covered by Health insurance Patient unable to understand and sign written informed consent. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with resectable colorectal liver metastasis - SamplingMethod: Non-Probability Sample